Conference Description:

Be at the forefront of the insights from 60+ leading experts as they share their learnings on:

Commercialization challenges, the payers perspective and the investors’ criteria for business in the current and future NASH market

The non-invasive diagnostics landscape and regulatory considerations on biomarker adoption for clinical trials

Computational methods and artificial intelligence to increase the efficiency of drug development

Scientific rationale of combinational therapeutics as the necessary treatment strategy for NASH to inform pairing decisions

Identification and recruitment of “high risk” patients needed to optimize clinical success and demonstrate sufficient efficacy

URLs:
Tickets https://go.evvnt.com/296641-0? pid=154
Brochure https://go.evvnt.com/296641-2 ?pid=154

Prices:
Gold Pass: Full Access (Conference Days + Seminar Day and Discussion Day): USD 4597.0,
Silver Pass: Conference + Seminar Day: USD 3898.0,
Silver Pass: Conference + Discussion Day (2 Workshops): USD 3898.0,
Bronze Pass: Conference Only: USD 2899.0,
Bronze Pass: Seminar Day Only: USD 1399.0,
Bronze Pass: Discussion Day Only (2 Workshops): USD 1399.0

Speakers: Adil Mardinoglu Professor of Systems Biology Kings College London, Allison Capone Global Strategic Marketing for Nonalcoholic Steatohepatitis Intercept, Anthony Samir Assistant Professor Harvard Medical School, Brent Tetri Director, Division of Gastroenterology and Hepatology; Professor of Internal Medicine Saint Louis University School of Medicine, Bryan Burkey Head of Pharmacology Zafgen, Bryan Fuchs Assistant in Molecular Biology Massachusetts General Hospital, Claus Kremoser Chief Executive Officer Phenex Pharmaceuticals, Dean Hum Senior Executive Vice President and Chief Scientific Officer Genfit, Diane Harbison Chief Executive Officer Stratified Medicine Scotland Innovation Centre, David Fraser Chief Scientific Officer NorthSea Therapeutics, Éric Lefebvre Chief Medical Officer Pliant Therapeutics, Etienne Sokal Chief Scientific and Medical Officer Promethera Biosciences, Glenn Rosen Independent Consultant, Greg Everson Chief Executive Officer HepQuant, Greg Tesz Principal Scientist Pfizer, H. James Harwood Adjunct Professor Department of Pathology Wake Forest University School of Medicine, Isai Peimer Biotech Analyst Surveyor Capital, Jagpreet Chhatwal Assistant Professor Harvard Medical School, James Conway Senior Scientist-Translational Bioinformatics MedImmune, Jelena Mann Professor of Epigenetics, Fibrosis Research Group Newcastle University, Jen-Chieh (Jay) Chuang Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences and Research Scientist Gilead, Jeff Irelan Director, Scientific Application Organovo, Julia Brosnan Senior Director, External Collaborations and Scientific Alliances Pfizer, Katie Brown Vice President, Support and Survivorship Program Lungevity (NASH Patient), Laura Brattain Research Scientist, Department of Radiology Massachusetts General Hospital, Laurent Fischer Senior Vice President Head Liver Therapeutic Area Allergan, Liat Hayardeny Chief Scientific Officer Galmed Pharmaceuticals, Linda Morrow Vice President and Chief Medical Officer ProSciento, Maria-Chiara Magnone Vice President, Metabolic Complications Janssen Research and Development, Marko Korenjak Vice President European Liver Patients Association, Manu Chakravarthy Chief Medical Officer and Senior Vice President Axcella Health, Matthews Bradley Founder, Chairman, President and Chief Technical Officer SAJE Pharma, Min Lu Director, Head of Fibrosis Morphic Therapeutics, Naim Alkhouri Director of the Metabolic Health Center Texas Liver Institute, Nikolai Naoumov Executive Director, Hepatology Sciences and Innovation Novartis and more.


Time: 8:00 am - 5:00 pm